Clinical trials: Large Bowel Cancer
Metastatic Colorectal Cancer
Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)
The purpose of this study is to determine safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) for the following combinations: pembrolizumab plus binimetinib (Cohort A), pembrolizumab plus…
- Trial name
- NCT03374254
- Testing
- Pembrolizumab, Binimetinib, Oxaliplatin
- Where
- 14 sites in United States, Canada
- Volunteers
- 116 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Colorectal Cancer
Adjuvant Aflibercept for Metastatic Colorectal Cancer
The main purpose of this study is to evaluate if aflibercept can reduce the chance that metastatic (spread of) colorectal cancer can grow back after finishing standard treatment.
- Trial name
- C261 (NCT01669720)
- Testing
- Aflibercept
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Brown University
Colorectal Cancer
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
This 2 arm study will assess the efficacy and safety of intermittent oral Xeloda, or iv fluorouracil/leucovorin, in combination with intravenous Eloxatin (oxaliplatin) in patients previously treated for metastatic colorectal…
- Trial name
- NCT00069108
- Testing
- 5 FU, Leucovorin, Oxaliplatin
- Where
- 87 sites in United States, Belgium and 18 more
- Volunteers
- 627 people
- Sponsor
- Hoffmann-La Roche
Advanced Colorectal Cancer
Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
This trial will evaluate the efficacy of PM060184 in terms of progression-free survival at 12 weeks (PFS3) in advanced or metastatic Colorectal Cancer (CRC) patients with any KRAS mutation status (wild- type; mutated; or unknown…
- Trial name
- NCT03427268
- Testing
- PM060184
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 32 people
- Sponsor
- PharmaMar
Pancreatic Adenocarcinoma, Ovarian Cancer
Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer
This Phase I/II trial evaluates LOAd703 in patients with cancer (pancreatic, biliary, colorectal or ovarian) together with their standard of care chemotherapy or using gemcitabine immune-conditioning.
- Conditions
- Pancreatic Adenocarcinoma, Ovarian Cancer, Biliary Carcinoma, Colorectal Cancer
- Trial name
- NCT03225989
- Testing
- LOAd703
- Where
- 2 sites in Sweden
- Volunteers
- 47 people
- Sponsor
- Lokon Pharma AB
Carcinoma of the Appendix, Colorectal Cancer
Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer
RATIONALE: Thalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Giving thalidomide after surgery and chemotherapy may kill any remaining tumor cells.
- Trial name
- NCT00310076
- Testing
- thalidomide, surgery
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Wake Forest University Health Sciences
Familial Adenomatous Polyposis
Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers
Primary Objective: To determine whether celecoxib downregulates GATA-6 expression to upregulate 15-LOX-1 expression and induce apoptosis in human rectal tumors, researchers will measure GATA-6 and 15-LOX-1 expression, 13-S-HODE…
- Trial name
- NCT00503035
- Testing
- Celecoxib, Colonoscopy Biopsy
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer
e-Motivación: Developing and Pilot Testing an App to Improve Latinos' Screening Colonoscopy Rates
Among Latinos, a fast growing and underserved population, Colorectal Cancer (CRC) is the third leading cause of cancer death in men and in women.
- Trial name
- NCT04987788
- Testing
- Motívate, Video link
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Colon Cancer, Colorectal Cancer
Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer
This study is for people with advanced colorectal cancer. This study uses the drugs Celebrex and EPO906. EPO906 is an experimental drug that has not been approved by the FDA.
- Trial name
- NCT00159484
- Testing
- EPO906, Celecoxib
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Southern California
Colorectal Cancer
A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer
This 2-arm study evaluated the efficacy and safety of 2 different treatment schedules of oral Xeloda with intravenous (IV) Eloxatin (oxaliplatin) and IV bevacizumab (Avastin) as a first-line treatment in patients with locally…
- Trial name
- NCT00118755
- Testing
- capecitabine, Oxaliplatin, bevacizumab
- Volunteers
- 435 people
- Sponsor
- Hoffmann-La Roche
Health Insurance, Colorectal Cancer Survivors
Virtual Health Insurance Navigation Pilot Program for Colorectal Survivors
This trial aims to assess the feasibility and acceptability of colorectal survivors approached and engaged in HINT and aims to assess the preliminary efficacy of HINT to improve 1) health insurance literacy and 2) financial…
- Trial name
- HINT-C (NCT05002608)
- Testing
- Health Insurance Navigation Tools Program
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts General Hospital
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
This clinical trial studies the side effects and best dose of giving fludarabine and total-body irradiation (TBI) together followed by a donor stem cell transplant and cyclosporine and mycophenolate mofetil in treating human…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00112593
- Testing
- fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Fred Hutchinson Cancer Center
Metastatic Colorectal Cancer
Sym004 in Patients With Advanced Solid Tumors
This trial is designed as a multi-centre, open label, dose-escalation, phase I trial and consists of five parts.
- Trial name
- NCT01117428
- Testing
- Sym004
- Where
- 7 sites in United States, Belgium and 1 more
- Volunteers
- 111 people
- Sponsor
- Symphogen A/S
Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
RATIONALE: Deferasirox may remove excess iron from the body caused by blood transfusions. PURPOSE: This clinical trial studies deferasirox in treating iron overload caused by blood transfusions in patients with hematologic…
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01273766
- Testing
- deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
Colon Cancer, Rectal Cancer
Stoma Closure and Reinforcement Trial
Hernia formation at sites of ostomy closure is a common complication. The investigator believes that using evidence based hernia repair techniques as a preventive measure during closure of ostomies will reduce the incidence of…
- Conditions
- Colon Cancer, Rectal Cancer, Ileostomy - Stoma
- Trial name
- SCAR (NCT03750461)
- Testing
- Mesh Implantation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer
Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery
This phase I/II trial studies the side effects and best dose of cetuximab when given together with pembrolizumab in treating patients with colorectal cancer that has spread from the primary site (place where it started) to other…
- Conditions
- Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
- Trial name
- NCT02713373
- Testing
- Cetuximab, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Roswell Park Cancer Institute
Colorectal Cancer
Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer
The purpose of this research study is to learn whether panitumumab helps treat colorectal cancer in participants who have not responded to treatment with cetuximab. Panitumumab is a human monoclonal antibody.
- Trial name
- NCT00842257
- Testing
- panitumumab
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Colorectal Cancer Metastatic
MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer
The primary goal of this study is to characterize the safety, tolerability, and maximum tolerated dose (MTD) of MGD007 when combined with MGA012.
- Trial name
- NCT03531632
- Testing
- MGD007 + MGA012
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- MacroGenics
Colorectal Cancer
A Study of Mitomycin C, Irinotecan, and Cetuximab
Colorectal cancer (CRC) is one of the more common cancers in the United States with over 145,000 new cases expected in 2005. Surgery is the main treatment for CRC.
- Trial name
- NCT00271011
- Testing
- Mitomycin C, Cetuximab, Irinotecan.
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Michigan Rogel Cancer Center
Colorectal Cancer
Increasing Colorectal Cancer Screening in a Safety-net Health System With a Focus on the Uninsured: Benefits and Costs
Colon cancer (CRC) is a leading cause of cancer death in the United States. Screening can prevent CRC death, but screening rates are suboptimal, especially for vulnerable populations such as those with limited or no health…
- Trial name
- NCT01191411
- Testing
- Mailed invitations for FIT test kits, Mailed invitations for a colonoscopy, Visit Based Care
- Volunteers
- 5,970 people
- Sponsor
- University of Texas Southwestern Medical Center